Denali Therapeutics Inc

NASDAQ:DNLI 4:00:00 PM EDT

14.96

-0.60 (-3.86%)

7:08:19 PM EDT: $14.96 0.00 (0.00%)

Market Cap (Intraday)	2.13B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$14.15 Million
Adjusted EPS	-$0.70

See more estimates

10-Day MA	$16.21
50-Day MA	$18.95
200-Day MA	$20.70

See more pivots

Denali Therapeutics Inc Stock, NASDAQ:DNLI

161 Oyster Point Boulevard, 2nd Floor, San Francisco, California 94080

United States of America

Phone: +1.615.866.8548

Number of Employees: 445

http://www.denalitherapeutics.com

Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.